Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUGAR: Single vs Multi-Dose Insulin for Glycemic Control
NCT07171684Recruiting
- Sponsor
- Rutgers University
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin glargine in gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Rutgers University. Primary endpoint: Composite neonatal outcome. Started Nov 2025; status: recruiting.
02
Drugs
insulin glargine
03
Conditions
gestational diabetes mellitus (GDM)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07171684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171684.